A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline

Completed · Phase 3

Conditions studied: Smoking Cessation

In brief

The primary purpose of this study is to obtain safety information on cigarette smokers treated with 52 weeks of varenicline regardless of smoking status.

Key facts

Study ID

NCT00143299

Run by

Pfizer

People needed

375

Starts

2003-10-01

Expected to finish

2005-03-01

Last updated by the study team

2007-06-04

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must have smoked an average of at least 10 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.

You may not qualify if…

• Subjects with clinically significant, recent cardiovascular disease.

Where it is running

• Pfizer Investigational Site — Denver, Colorado, United States
• Pfizer Investigational Site — Milford, Massachusetts, United States
• Pfizer Investigational Site — Albuquerque, New Mexico, United States
• Pfizer Investigational Site — Syracuse, New York, United States
• Pfizer Investigational Site — Charlotte, North Carolina, United States
• Pfizer Investigational Site — Oklahoma City, Oklahoma, United States
• Pfizer Investigational Site — Harleysville, Pennsylvania, United States
• Pfizer Investigational Site — Richmond, Virginia, United States
• Pfizer Investigational Site — Woodville South, South Australia, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.